Physician profile
Mary Masterman
NPI 1225487655
$259.20
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $218 · 2021: $41.16.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $98.52 | 2020 | |
| Sanofi-Aventis U.S. LLC | $59.91 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $25.14 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $23.38 | 2020 | |
| Nevro Corp. | $20.16 | 2020 | |
| Amgen INC. | $16.46 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.63 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Masterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.